Your browser doesn't support javascript.
loading
Lost in translation: returning germline genetic results in genome-scale cancer research.
Johns, Amber L; McKay, Skye H; Humphris, Jeremy L; Pinese, Mark; Chantrill, Lorraine A; Mead, R Scott; Tucker, Katherine; Andrews, Lesley; Goodwin, Annabel; Leonard, Conrad; High, Hilda A; Nones, Katia; Patch, Ann-Marie; Merrett, Neil D; Pavlakis, Nick; Kassahn, Karin S; Samra, Jaswinder S; Miller, David K; Chang, David K; Pajic, Marina; Pearson, John V; Grimmond, Sean M; Waddell, Nicola; Zeps, Nikolajs; Gill, Anthony J; Biankin, Andrew V.
Afiliação
  • Johns AL; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • McKay SH; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • Humphris JL; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • Pinese M; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • Chantrill LA; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • Mead RS; St Vincents Hospital, Darlinghurst, Australia.
  • Tucker K; Western Sydney University Clinical School, Sydney, Australia.
  • Andrews L; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • Goodwin A; Genetics Department, SEALS Pathology, Prince of Wales Hospital, Randwick, Sydney, Australia.
  • Leonard C; School of Medicine, University of New South Wales, Sydney, Australia.
  • High HA; Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Sydney, Australia.
  • Nones K; Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Sydney, Australia.
  • Patch AM; Cancer Genetics Department, Royal Prince Alfred Hospital and Liverpool Hospital, Sydney, NSW, Australia.
  • Merrett ND; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Pavlakis N; Sydney Cancer Genetics, Sydney, Australia.
  • Kassahn KS; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Samra JS; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Miller DK; Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, Australia.
  • Chang DK; Division of Surgery, School of Medicine, Western Sydney University, Sydney, Australia.
  • Pajic M; Department of Medical Oncology, Royal North Shore Hospital and Faculty of Medicine, University of Sydney, Sydney, Australia.
  • Pearson JV; Department of Surgery, Royal North Shore Hospital, Sydney, Australia.
  • Grimmond SM; Illumina Inc, 5200 Illumina Way, San Diego, CA, 92122, USA.
  • Waddell N; Cancer Research Program, Garvan Institute of Medical Research, Kinghorn Cancer Centre, Sydney, Australia.
  • Zeps N; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK.
  • Gill AJ; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
  • Biankin AV; Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, Australia.
Genome Med ; 9(1): 41, 2017 04 28.
Article em En | MEDLINE | ID: mdl-28454591
BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. METHODS: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium-high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. RESULTS: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. CONCLUSION: Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Genoma Humano / Mutação em Linhagem Germinativa / Predisposição Genética para Doença Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Genoma Humano / Mutação em Linhagem Germinativa / Predisposição Genética para Doença Idioma: En Ano de publicação: 2017 Tipo de documento: Article